Lipidosterolic extract of Serenoa repens.
The hard capsules are pale green and contain a greenish yellow paste with a characteristic odour.
Each hard capsule contains 160 mg lipidosterolic extract of Serenoa repens*.
*Oil extract originated from fruits of Serenoa repens (Bartram) Small.
Drug extract ratio: 7-11:1.
Extraction solvent: Hexanic solvent.
Excipients/Inactive Ingredients: The other components are macrogol 10,000, gelatin, yellow iron oxide E 172, indigotin E 132, titanium dioxide E 171.
Pharmacology: Pharmacodynamics/Pharmacokinetics: PERMIXON belongs to the group of medicines used in benign prostatic hypertrophy and acts at the prostatic level improving the symptoms associated with benign prostatic hypertrophy.
PERMIXON is indicated in male adult for treatment of functional signs due to benign prostatic hyperplasia (prostatic adenoma): abnormally frequent micturitions, especially at night, decrease of the volume and the strength of the urinary stream, pelvic congestion.
Recommended dose: Always take PERMIXON exactly as the doctor has told. If the patient has any further questions, ask the doctor or pharmacist.
The recommended dose is one capsule, twice per day, at meals, with the help of a little bit of water.
Mode of administration: Take with a glass of water.
Overdose and Treatment: The appearance of symptoms is transient gastrointestinal disorders (abdominal pain).
In case of overdose or accidental ingestion, consult a doctor or pharmacist.
Do not take PERMIXON if the patient is allergic to the active substance lipidosterolic extract of Serenoa repens or to any of the other ingredients of this medicine (listed in Description).
Talk to a doctor or pharmacist before taking PERMIXON.
Drug administration on empty stomach may cause nausea and should therefore be administered with meals.
PERMIXON cannot substitute prostatectomy and, during treatment, the patient must be under continuous medical surveillance.
This medicinal product is not indicated in women.
Ask a doctor or pharmacist for advice before using any medicine.
Like all medicines, PERMIXON can cause side effects, although not everybody gets them. The side effects that can occur are:
Commonly (affect 1 to 10 in 100 people): Headache, Abdominal pain.
Uncommonly (affect 1 to 10 in 1000 people): Nausea, Increase of Gamma-Glutamyltransferase, moderate increase of transaminases (liver enzymes), Reddening of the skin (rash), Gynecomastia (enlargement of mammary glands in men). Reversible upon discontinuation of treatment.
With an unknown frequency (frequency cannot be estimated from the available data): Oedema.
Reporting of side effects: If the patient gets any side effects, talk to the doctor or pharmacist. This includes any possible side effects not listed in this monograph. The patient can also report side effects directly via the national reporting system. By reporting side effects, the patient can help provide more information on the safety of this medicine.
Tell the doctor or pharmacist if the patient is using, has recently used or might use any other medicines.
No interferences with other medicines frequently used to treat this disease (urinary antibiotics, antiseptics and anti-inflammatory agents) have been observed. To avoid possible interactions between several medicines, the patient must tell the doctor or pharmacist all other treatments that he/she is following.
Do not store above 25°C.
Do not throw away medicines via waste water or household waste. Ask a pharmacist on how to throw away medicines that the patient no longer use. These measures will help protect the environment.
G04CX - Other drugs used in benign prostatic hypertrophy ; Used in the treatment of benign prostatic hypertrophy.
Permixon hard cap 160 mg
2 × 15's
Sign Out
